1. Home
  2. LQDA vs QLYS Comparison

LQDA vs QLYS Comparison

Compare LQDA & QLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LQDA

Liquidia Corporation

HOLD

Current Price

$38.56

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Logo Qualys Inc.

QLYS

Qualys Inc.

HOLD

Current Price

$88.41

Market Cap

3.0B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
LQDA
QLYS
Founded
2004
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.0B
IPO Year
2020
2012

Fundamental Metrics

Financial Performance
Metric
LQDA
QLYS
Price
$38.56
$88.41
Analyst Decision
Strong Buy
Hold
Analyst Count
11
13
Target Price
$41.00
$133.08
AVG Volume (30 Days)
966.9K
835.7K
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
51.81
16.99
EPS
N/A
5.44
Revenue
$158,320,000.00
$321,607,000.00
Revenue This Year
$278.87
$9.97
Revenue Next Year
$57.13
$7.15
P/E Ratio
N/A
$16.58
Revenue Growth
1031.18
15.32
52 Week Low
$11.85
$74.51
52 Week High
$46.67
$155.47

Technical Indicators

Market Signals
Indicator
LQDA
QLYS
Relative Strength Index (RSI) 54.43 50.87
Support Level $35.00 $83.60
Resistance Level $39.19 $92.02
Average True Range (ATR) 1.83 4.01
MACD -0.11 1.17
Stochastic Oscillator 46.61 75.87

Price Performance

Historical Comparison
LQDA
QLYS

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

About QLYS Qualys Inc.

Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.

Share on Social Networks: